Santarus obtained FDA approval to market its nonprescription version of Schering-Plough's heartburn drug Zegerid. The specialty-drug company will get a milestone payment of $20 million from a unit of Schering-Plough and is required to pay the University of Missouri royalties on net sales of the product.

Full Story:

Related Summaries